Showing 1 - 10 of 44,364
, particularly from an economic standpoint. In this regard, pharmaceuticals are not generally traded in what might be described as a … with the overall regulatory schemes. A drug that is not approved for marketing in a particular country does not become so … because it is imported. Parallel trade (i.e., imports and exports) in pharmaceuticals takes place in markets that are …
Persistent link: https://www.econbiz.de/10014124812
Persistent link: https://www.econbiz.de/10011405941
Policy makers need reliable estimates of direct costs of pharmaceutical R&D, in order to contain health-care costs and at the same time maintain a supportive environment for investment in research. This paper evaluates the application of parametric estimating methods to the late stage clinical...
Persistent link: https://www.econbiz.de/10014224317
Persistent link: https://www.econbiz.de/10010388964
Persistent link: https://www.econbiz.de/10011741304
Persistent link: https://www.econbiz.de/10001514275
This paper studies the contribution of doctor and patient 'habit' to persistence in market shares in prescription drug markets. My unique panel dataset allows me to estimate the probability of switching brands as a function of patient and doctor attributes, with an emphasis on past prescribing...
Persistent link: https://www.econbiz.de/10014146880
pharmaceuticals to examine how incumbents respond to change in the threat of entry. In line with the entry deterrence motive …
Persistent link: https://www.econbiz.de/10012285099
Persistent link: https://www.econbiz.de/10013485280
Persistent link: https://www.econbiz.de/10015077056